Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has announced its participation in two upcoming investor conferences in September 2024:

• The Wells Fargo 2024 Healthcare Conference in Boston, with a fireside chat on September 5 at 1:30 p.m. ET
• The Baird 2024 Global Healthcare Conference in New York City, featuring a fireside chat on September 11 at 1:25 p.m. ET

Webcasts of the presentations will be available on the Investors section of Voyager's website and archived for at least 30 days. This announcement highlights Voyager's engagement with investors and its commitment to sharing updates on its progress in the field of neurogenetic medicine.

LEXINGTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in multiple upcoming investor conferences:

• The Wells Fargo 2024 Healthcare Conference, in Boston, including a fireside chat at 1:30 p.m. ET on September 5, 2024
• The Baird 2024 Global Healthcare Conference, in New York City, including a fireside chat at 1:25 p.m. ET on September 11, 2024

Webcasts of any presentations may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com. A replay of the webcasts will be archived on the Company's website for at least 30 days.

About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit www.voyagertherapeutics.com.

Voyager Therapeutics^® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.

Contacts
Trista Morrison, NACD.DC, tmorrison@vygr.com
Investors: Adam Bero, Ph.D., abero@kendallir.com
Media: Brooke Shenkin, brooke@scientpr.com

FAQ

What investor conferences will Voyager Therapeutics (VYGR) attend in September 2024?

Voyager Therapeutics will attend the Wells Fargo 2024 Healthcare Conference in Boston on September 5, and the Baird 2024 Global Healthcare Conference in New York City on September 11, 2024.

When is Voyager Therapeutics' (VYGR) fireside chat at the Wells Fargo 2024 Healthcare Conference?

Voyager Therapeutics' fireside chat at the Wells Fargo 2024 Healthcare Conference is scheduled for September 5, 2024, at 1:30 p.m. ET.

Where can I watch the webcasts of Voyager Therapeutics' (VYGR) investor conference presentations?

Webcasts of Voyager Therapeutics' presentations can be accessed from the Investors section of the company's website at ir.voyagertherapeutics.com.

How long will the webcasts of Voyager Therapeutics' (VYGR) investor presentations be available?

The webcasts of Voyager Therapeutics' investor presentations will be archived on the company's website for at least 30 days.